Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

August 01, 2020; Volume 374,Issue 2

Behavioral Pharmacology

  • You have access
    Pharmacological Properties of δ-Opioid Receptor–Mediated Behaviors: Agonist Efficacy and Receptor Reserve
    Isaac J. Dripps, Ruizhuo Chen, Amanda M. Shafer, Kathryn E. Livingston, Alexander Disney, Stephen M. Husbands, John R. Traynor, Kenner C. Rice and Emily M. Jutkiewicz
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 319-330; DOI: https://doi.org/10.1124/jpet.119.262717

Cellular and Molecular

  • Open Access
    ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins
    Daniel K. Crawford, Iris Alroy, Neal Sharpe, Matthew M. Goddeeris and Greg Williams
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 264-272; DOI: https://doi.org/10.1124/jpet.120.265595
  • Open Access
    Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone
    Leilei Zhang, Danyelle M. Townsend, Morgan Morris, Eduardo N. Maldonado, Yu-Lin Jiang, Ann-Marie Broome, Jennifer R. Bethard, Lauren E. Ball and Kenneth D. Tew
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 308-318; DOI: https://doi.org/10.1124/jpet.120.000009

Drug Discovery and Translational Medicine

  • You have access
    Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures
    Etienne Guillot, Jean-Christophe Le Bail, Pascal Paul, Valérie Fourgous, Pascale Briand, Michel Partiseti, Bruno Cornet, Philip Janiak and Christophe Philippo
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 283-294; DOI: https://doi.org/10.1124/jpet.120.265454
  • Open Access
    Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease
    Ughetta del Balzo, Pierre E. Signore, Gail Walkinshaw, Todd W. Seeley, Mitchell C. Brenner, Qingjian Wang, Guangjie Guo, Michael P. Arend, Lee A. Flippin, F. Aisha Chow, David C. Gervasi, Christian H. Kjaergaard, Ingrid Langsetmo, Volkmar Guenzler, David Y. Liu, Steve J. Klaus, Al Lin and Thomas B. Neff
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 342-353; DOI: https://doi.org/10.1124/jpet.120.265181

Metabolism, Transport, and Pharmacogenomics

  • You have access
    Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People
    Matthew G. McDonald, Lindsay M. Henderson, Sutapa Ray, Catherine K. Yeung, Amanda L. Johnson, John P. Kowalski, Helmut Hanenberg, Constanze Wiek, Kenneth E. Thummel and Allan E. Rettie
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 233-240; DOI: https://doi.org/10.1124/jpet.120.265850
  • You have access
    In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate
    Wee Kiat Tan, Alyssa Rui Yi Tan, Punitha Sivanandam, Ernest Jing Hui Goh, Ze Ping Yap, Nur Fazilah Saburulla, Karl Austin-Muttitt, Jonathan G.L. Mullins and Aik Jiang Lau
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 295-307; DOI: https://doi.org/10.1124/jpet.120.265249

Neuropharmacology

  • [<sup>3</sup>H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein
    You have access
    [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein
    Matthew Strauss, Bernadette O’Donovan, Yizhi Ma, Ziyu Xiao, Steven Lin, Michael T. Bardo, Pavel I. Ortinski, Jay P. McLaughlin and Jun Zhu
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 241-251; DOI: https://doi.org/10.1124/jpet.120.266023
  • Open Access
    MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy
    Xiaohai Wang, Wenping Li, Jacob Marcus, Michelle Pearson, Lixin Song, Karen Smith, Giuseppe Terracina, Julie Lee, Kwok-Lam Karen Hong, Sherry X. Lu, Lynn Hyde, Shu-Cheng Chen, David Kinsley, Jerry P. Melchor, Daniel J. Rubins, Xiangjun Meng, Eric Hostetler, Cyrille Sur, Lili Zhang, Joel B. Schachter, J. Fred Hess, Harold G. Selnick, David J. Vocadlo, Ernest J. McEachern, Jason M. Uslaner, Joseph L. Duffy and Sean M. Smith
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 252-263; DOI: https://doi.org/10.1124/jpet.120.266122
  • You have access
    3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters
    Charlotte P. Magee, Christopher L. German, Yasmeen H. Siripathane, Peter S. Curtis, David J. Anderson, Diana G. Wilkins, Glen R. Hanson and Annette E. Fleckenstein
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 273-282; DOI: https://doi.org/10.1124/jpet.119.264895
  • You have access
    Chronic Morphine-Induced Changes in Signaling at the A3 Adenosine Receptor Contribute to Morphine-Induced Hyperalgesia, Tolerance, and Withdrawal
    Timothy M. Doyle, Tally M. Largent-Milnes, Zhoumou Chen, Vasiliki Staikopoulos, Emanuela Esposito, Rebecca Dalgarno, Churmy Fan, Dilip K. Tosh, Salvatore Cuzzocrea, Kenneth A. Jacobson, Tuan Trang, Mark R. Hutchinson, Gary J. Bennett, Todd W. Vanderah and Daniela Salvemini
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 331-341; DOI: https://doi.org/10.1124/jpet.120.000004
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics: 374 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 374, Issue 2
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Behavioral Pharmacology
  • Cellular and Molecular
  • Drug Discovery and Translational Medicine
  • Metabolism, Transport, and Pharmacogenomics
  • Neuropharmacology
  • Most Read
Loading
  • Potential Clinical Uses of CBG
  • Ocular Drug Delivery: Past, Present, and Future
  • Nose-to-Brain Delivery
  • Antipsychotic-VMAT2 Inhibitor Synergy: Schizophrenia Models
  • SEP-363856, a Novel, Non-D2 Psychotropic Agent
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics